The active substance of Meprelon belongs to the family of modified adrenocortical hormones (glucocorticoids). Meprelon contains a high dose of the active substance in a form sparingly soluble in water. Therefore, Meprelon is administered directly into the bloodstream in acute, life-threatening conditions that require glucocorticoid therapy. Meprelon is used in acute, life-threatening conditions such as:
- shock associated with severe systemic allergic reaction (anaphylactic shock)
- after previous administration of noradrenaline (a drug acting on the circulatory system),
- cerebral oedema (only in case of symptoms of increased intracranial pressure demonstrated by computed tomography) caused by a brain tumour, neurosurgical procedures, brain abscess, bacterial meningitis;
- persisting shock lung (Adult Respiratory Distress Syndrome – ARDS) after the acute phase, severe acute asthma attack;
- severe systemic bacterial infection with adrenocortical insufficiency (Waterhouse–Friderichsen syndrome),
- risk of organ rejection after kidney transplantation;
- accumulation of water in lung tissues following inhalation of toxic gases (toxic pulmonary oedema).